Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis.
The protective capabilities of three Leishmania recombinant proteins - histone 1 (H1) and hydrophilic acylated surface protein B1 (HASPB1) immunized singly, or together as a protein cocktail vaccine with Montanide, and the polyprotein MML immunized with MPL-SE adjuvant - were assessed in beagle dogs. Clinical examination of the dogs was carried out periodically under blinded conditions and the condition of the dogs defined as asymptomatic or symptomatic. At the end of the trial, we were able to confirm that following infection with L. infantum promastigotes, five out of eight dogs immunized with H1 Montanide, and four out of eight dogs immunized with either the combination of HASPB1 with Montanide or the combination of H1+HASPB1 with Montanidetrade mark, remained free of clinical signs, compared with two out of seven dogs immunized with the polyprotein MML and adjuvant MPL-SE, and two out of eight dogs in the control group. The results demonstrate that HASPB1 and H1 antigens in combination with Montanide were able to induce partial protection against canine leishmaniasis, even under extreme experimental challenge conditions.
Moreno
J
J
WHO Collaborating Centre for Leishmaniasis, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Spain. javier.moreno@cib.csic.es
Nieto
J
J
Masina
S
S
Cañavate
C
C
Cruz
I
I
Chicharro
C
C
Carrillo
E
E
Napp
S
S
Reymond
C
C
Kaye
P M
PM
Smith
D F
DF
Fasel
N
N
Alvar
J
J
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood; D000953:Antigens, Protozoan / Q000276:immunology*; D001774:Blood Chemical Analysis; D001835:Body Weight; D049109:Cell Proliferation; D004283:Dog Diseases / Q000276:immunology / Q000503:physiopathology / Q000517:prevention & control*; D004285:Dogs; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D007891:Leishmania / Q000276:immunology*; D007896:Leishmaniasis / Q000276:immunology / Q000503:physiopathology / Q000517:prevention & control / Q000662:veterinary*; D007963:Leukocytes, Mononuclear / Q000276:immunology; D008297:Male; D016052:Protozoan Vaccines / Q000276:immunology*; D022223:Vaccines, Subunit / Q000276:immunology; D014614:Vaccines, Synthetic / Q000276:immunology
D000276:Adjuvants, Immunologic; D000913:Antibodies, Protozoan; D000953:Antigens, Protozoan; D016052:Protozoan Vaccines; D022223:Vaccines, Subunit; D014614:Vaccines, Synthetic